Cargando…

A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5

BACKGROUND: Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Fan, Xin, Zhang, Yue, Huang, Limei, Jiang, Tingting, Qin, Zailong, Su, Jiasun, Luo, Jingrong, Yi, Shang, Zhang, Shujie, Shen, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216669/
https://www.ncbi.nlm.nih.gov/pubmed/32393339
http://dx.doi.org/10.1186/s12881-020-01039-5
_version_ 1783532459843911680
author Li, Wei
Fan, Xin
Zhang, Yue
Huang, Limei
Jiang, Tingting
Qin, Zailong
Su, Jiasun
Luo, Jingrong
Yi, Shang
Zhang, Shujie
Shen, Yiping
author_facet Li, Wei
Fan, Xin
Zhang, Yue
Huang, Limei
Jiang, Tingting
Qin, Zailong
Su, Jiasun
Luo, Jingrong
Yi, Shang
Zhang, Shujie
Shen, Yiping
author_sort Li, Wei
collection PubMed
description BACKGROUND: Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature death. CLN5 was initially named Finnish variant late infantile NCL, it is now known to be present in other ethnic populations and with variable age of onset. Few CLN5 patients had been reported in Chinese population. CASE PRESENTATION: In this paper, we report the symptoms of a Chinese patient who suffer from developmental regression and grand mal epilepsy for several years. The DNA was extracted from peripheral blood of proband and both parents, and then whole exome sequencing was performed using genomic DNA. Both sequence variants and copy number variants (CNVs) were analyzed and classified according to guidelines. As the result, a novel frameshift mutation c.718_719delAT/p.Met240fs in CLN5 and a de novo large deletion at 13q21.33-q31.1 which unmasked the frameshift mutation were identified in the proband. Despite the large de novo deletion, which can be classified as a pathogenic copy number variant (CNV), the patient’s clinical presentation is mostly consistent with that of CLN5, except for early developmental delay which is believed due to the large deletion. Both variants were detected simultaneously by exome sequencing. CONCLUSIONS: This is the first report of whole gene deletion in combination with a novel pathogenic sequence variant in a CLN5 patient. The two mutations detected with whole exome sequencing simultaneously proved the advantage of the sequencing technology for genetic diagnostics.
format Online
Article
Text
id pubmed-7216669
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72166692020-05-18 A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5 Li, Wei Fan, Xin Zhang, Yue Huang, Limei Jiang, Tingting Qin, Zailong Su, Jiasun Luo, Jingrong Yi, Shang Zhang, Shujie Shen, Yiping BMC Med Genet Case Report BACKGROUND: Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature death. CLN5 was initially named Finnish variant late infantile NCL, it is now known to be present in other ethnic populations and with variable age of onset. Few CLN5 patients had been reported in Chinese population. CASE PRESENTATION: In this paper, we report the symptoms of a Chinese patient who suffer from developmental regression and grand mal epilepsy for several years. The DNA was extracted from peripheral blood of proband and both parents, and then whole exome sequencing was performed using genomic DNA. Both sequence variants and copy number variants (CNVs) were analyzed and classified according to guidelines. As the result, a novel frameshift mutation c.718_719delAT/p.Met240fs in CLN5 and a de novo large deletion at 13q21.33-q31.1 which unmasked the frameshift mutation were identified in the proband. Despite the large de novo deletion, which can be classified as a pathogenic copy number variant (CNV), the patient’s clinical presentation is mostly consistent with that of CLN5, except for early developmental delay which is believed due to the large deletion. Both variants were detected simultaneously by exome sequencing. CONCLUSIONS: This is the first report of whole gene deletion in combination with a novel pathogenic sequence variant in a CLN5 patient. The two mutations detected with whole exome sequencing simultaneously proved the advantage of the sequencing technology for genetic diagnostics. BioMed Central 2020-05-11 /pmc/articles/PMC7216669/ /pubmed/32393339 http://dx.doi.org/10.1186/s12881-020-01039-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Li, Wei
Fan, Xin
Zhang, Yue
Huang, Limei
Jiang, Tingting
Qin, Zailong
Su, Jiasun
Luo, Jingrong
Yi, Shang
Zhang, Shujie
Shen, Yiping
A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5
title A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5
title_full A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5
title_fullStr A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5
title_full_unstemmed A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5
title_short A novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a Chinese patient with neuronal ceroid lipofuscinosis type 5
title_sort novel pathogenic frameshift variant unmasked by a large de novo deletion at 13q21.33-q31.1 in a chinese patient with neuronal ceroid lipofuscinosis type 5
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216669/
https://www.ncbi.nlm.nih.gov/pubmed/32393339
http://dx.doi.org/10.1186/s12881-020-01039-5
work_keys_str_mv AT liwei anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT fanxin anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT zhangyue anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT huanglimei anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT jiangtingting anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT qinzailong anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT sujiasun anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT luojingrong anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT yishang anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT zhangshujie anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT shenyiping anovelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT liwei novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT fanxin novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT zhangyue novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT huanglimei novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT jiangtingting novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT qinzailong novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT sujiasun novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT luojingrong novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT yishang novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT zhangshujie novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5
AT shenyiping novelpathogenicframeshiftvariantunmaskedbyalargedenovodeletionat13q2133q311inachinesepatientwithneuronalceroidlipofuscinosistype5